Send us Feedback

UnitedHealth Group (UNH)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

UNH » Topics » Key Developments

This excerpt taken from the UNH 8-K filed Jan 18, 2007.

Key Developments

 

  •   Ingenix fourth quarter revenues of $304 million increased more than 20 percent year-over-year and sequentially. Advances were driven by the seasonal demand for Ingenix syndicated content products and strong software sales. Ingenix full year revenues of $975 million also increased by more than 20 percent year-over-year.

 

  •   Fourth quarter earnings from operations at Ingenix reached $77 million, bringing full year earnings from operations to $191 million. The fourth quarter operating margin of 25.3 percent was seasonally strong, as expected, and brought the full year operating margin up to 19.6 percent.

 

  •   Strong sales performance continued in the fourth quarter, with the Ingenix contract revenue backlog exceeding $1.1 billion across its business units on December 31, 2006, a year-over-year increase of 30 percent.

 

10 of 12

This excerpt taken from the UNH 8-K filed Oct 19, 2006.

Key Developments

 

  •   Ingenix revenues increased $39 million, or 19 percent year-over-year, to $244 million in the third quarter of 2006, reflecting strong growth across the full scope of Ingenix product lines.

 

  •   The Ingenix contract revenue backlog across its diverse product lines increased nearly 40 percent year-over-year to more than $1.1 billion.

 

  •   Ingenix continued to see strong momentum in the third quarter in key market segments and product categories. Significant new business contracts in the quarter included clinical research, statistical analysis and safety services for pharmaceutical companies, decision-support tools for payers and insurers, and technologies for managing and reporting information about networks of medical service providers.

 

  •   Ingenix third quarter earnings from operations increased $13 million or 30 percent year-over-year and increased $24 million or 75 percent sequentially. The third quarter operating margin of 23.0 percent increased 200 basis points year-over-year and 780 basis points from the second quarter of 2006. The operating margin gains reflected the expected third quarter seasonal increase in physician and provider market sales and the benefit of a growing revenue base paired with effective operating cost management.

This excerpt taken from the UNH 8-K filed Jul 19, 2006.

Key Developments

 

  •   Ingenix revenues increased $36 million, or 21 percent year-over-year, to $211 million in the second quarter of 2006, reflecting strong growth across the full scope of Ingenix product lines.

 

  •   The Ingenix contract revenue backlog across its diverse product lines reached more than $1.05 billion at June 30, 2006. This compares to backlog levels of $822 million for the comparable prior-year period and $850 million as of year-end 2005, highlighting growing revenue momentum.

 

  •   New sales activity in the second quarter included significant new orders in pharmaceutical safety and research services, decision-support tools, fraud and recovery services, and technologies to collect, analyze and manage medical cost data.

 

  •   Ingenix second quarter earnings from operations increased $9 million or 39 percent year-over-year and decreased $2 million or 6 percent sequentially. The second quarter operating margin of 15.2 percent declined 180 basis points from first quarter 2006 and increased 210 basis points year-over-year. The sequential reduction in operating margin in the second quarter was due to increased new product development and marketing activities, as well as the typical seasonal slowdown in shipments of coding and referential products to the physician and provider market segment.

 

  •   Ingenix anticipates sequential gains in revenues, earnings from operations and operating margin in the second half of 2006 as compared to the first six months, as product revenues are expected to again increase seasonally in the second half of the year.

This excerpt taken from the UNH 8-K filed Jan 19, 2006.

Key Developments

 

  •   Ingenix fourth quarter revenues of $248 million increased $34 million or 16 percent year-over-year and $43 million or 21 percent sequentially. Advances were driven by the seasonal pick-up for Ingenix syndicated content products and strong software sales. On a full year basis, Ingenix grew revenues by $124 million or 19 percent over 2004 results.

 

  •   Strong sales performance continued in the fourth quarter, with the Ingenix contract revenue backlog exceeding $850 million across its business units on December 31, 2005, a year-over-year increase of 28 percent.

 

  •   Ingenix earnings from operations increased $19 million or 34 percent year-over-year and $26 million or 53 percent on a sequential quarter basis. Full year earnings from operations increased $48 million or 37 percent to $177 million. The fourth quarter operating margin of 30.2 percent expanded 4 percentage points year-over-year, bringing the full year 2005 operating margin up to 22.3 percent. Exceptional earnings leverage, particularly from data, software and informatics products, drove the year-over-year and sequential operating margin gains.

This excerpt taken from the UNH 8-K filed Oct 14, 2005.

Key Developments

 

  •   Ingenix revenues increased $35 million, or 21 percent year-over-year, to $205 million in the third quarter of 2005.

 

  •   The Ingenix contract revenue backlog grew 25 percent year-over-year, due to strong customer demand for software products that enable payers, employers and other intermediaries to obtain a detailed understanding of medical costs and trends, software tools that improve business operations for medical service providers, and consulting and outsourced services.

 

  •   During the third quarter, the U.S. Food and Drug Administration announced it will utilize Ingenix i3 Aperio™ software and analytic consulting services to help improve the effectiveness and speed of safety evaluations for pharmaceutical agents that have been approved for use in the U.S. market.

 

  •   Ingenix earnings from operations increased $15 million, or 44 percent year-over-year, and the operating margin increased to 23.9 percent, up 390 basis points from third quarter 2004, due to strong contribution margins on consulting services and software product sales, as well as focused operating cost disciplines across its businesses.

This excerpt taken from the UNH 8-K filed Jul 14, 2005.

Key Developments

 

  •   Ingenix revenues increased $29 million, or 20 percent year-over-year, to $175 million in the second quarter of 2005, reflecting strong performance across the full scope of Ingenix product lines.

 

  •   The Ingenix contract revenue backlog across its diverse product lines reached $822 million at June 30, 2005. This compares to backlog levels of $646 million for the comparable prior year period and $665 million as of year-end 2004, demonstrating the growing revenue momentum building within this business.

 

  •   Ingenix second quarter operating earnings increased $9 million or 45 percent year-over-year and $5 million or 21 percent sequentially. Operating margin increased to 16.6 percent, up 210 basis points from first quarter 2005 and 290 basis points year-over-year. The results reflect the combination of strong contribution margins on consulting services and data and software product sales, as well as focused operating efficiencies across its business lines.

 

  •   During the second quarter Ingenix announced the launch of i3 Aperio, an advanced drug registry tool that will allow drug manufacturers and regulators to access data on the safety of newly introduced drugs faster and more efficiently than ever before.

This excerpt taken from the UNH 8-K filed Apr 14, 2005.

Key Developments

 

  •   Ingenix revenues increased $26 million, or 19 percent year-over-year, to $166 million in the first quarter of 2005. This gain reflects strong growth performance and provides the most meaningful measure of Ingenix results, due to the markedly seasonal sales characteristics of some key product lines.

 

  •   A diversified group of U.S., European and Japanese life sciences companies executed clinical research service agreements in the first quarter, including 12 contracts with total values of at least $1 million each.

 

  •   Ingenix secured significant orders in the first quarter from a broad variety of payers and providers for software and database products related to claims data, editing and management.

 

  •   The Ingenix revenue backlog grew 17 percent on a year-over-year basis and currently represents approximately 80 percent of its 2005 revenue expectation.

 

  •   Ingenix first quarter operating earnings increased $5 million or 26 percent year-over-year to $24 million, and the operating margin increased to 14.5 percent, up 90 basis points from first quarter 2004. The results reflect the combination of strong contribution margins on software system sales and focused operating efficiencies across its business lines.

This excerpt taken from the UNH 8-K filed Jan 20, 2005.

Key Developments

 

  • Ingenix fourth quarter revenues increased $35 million or 20 percent year-over-year and $44 million or 26 percent sequentially, to $214 million in the fourth quarter of 2004. Advances were driven by the seasonal pick-up for Ingenix syndicated content products and software and a year-over-year increase in pharmaceutical services revenues.

 

  • Insurance companies, employers and other benefits payers executed significant fourth quarter purchases of proprietary Ingenix technology, including major orders for Symmetry analytic software for disease and condition identification, significant purchases of PowerTrak medical bill adjudication automation software, and strong orders for advanced claims editing systems. Ingenix also had strong sales for its ClaimsManager software packages that enable health delivery systems to optimize their billing efficiency.

 

  • On a full year basis, Ingenix grew revenues by $96 million or 17 percent over 2003 results, led by strong broad-based growth in its health informatics offerings.

 

  • Ingenix operating earnings increased $24 million or 75 percent year-over-year and $22 million or 65 percent on a sequential quarter basis. Full year operating earnings increased $54 million or 72 percent as operating margin expanded more than 6 percentage points to 19.3 percent. Exceptional earnings leverage from both improving performance on pharmaceutical services and strong contributions from data, software and informatics products provided the year-over-year and sequential earnings gains.

This excerpt taken from the UNH 8-K filed Jan 20, 2005.

Key Developments

 

  • Ingenix fourth quarter revenues increased $35 million or 20 percent year-over-year and $44 million or 26 percent sequentially, to $214 million in the fourth quarter of 2004. Advances were driven by the seasonal pick-up for Ingenix syndicated content products and software and a year-over-year increase in pharmaceutical services revenues.

 

  • Insurance companies, employers and other benefits payers executed significant fourth quarter purchases of proprietary Ingenix technology, including major orders for Symmetry analytic software for disease and condition identification, significant purchases of PowerTrak medical bill adjudication automation software, and strong orders for advanced claims editing systems. Ingenix also had strong sales for its ClaimsManager software packages that enable health delivery systems to optimize their billing efficiency.

 

  • On a full year basis, Ingenix grew revenues by $96 million or 17 percent over 2003 results, led by strong broad-based growth in its health informatics offerings.

 

  • Ingenix operating earnings increased $24 million or 75 percent year-over-year and $22 million or 65 percent on a sequential quarter basis. Full year operating earnings increased $54 million or 72 percent as operating margin expanded more than 6 percentage points to 19.3 percent. Exceptional earnings leverage from both improving performance on pharmaceutical services and strong contributions from data, software and informatics products provided the year-over-year and sequential earnings gains.

EXCERPTS ON THIS PAGE:

8-K
Jan 18, 2007
8-K
Oct 19, 2006
8-K
Jul 19, 2006
8-K
Jan 19, 2006
8-K
Oct 14, 2005
8-K
Jul 14, 2005
8-K
Apr 14, 2005
8-K
Jan 20, 2005
8-K
Jan 20, 2005

RELATED TOPICS for UNH:

"Key Developments" elsewhere:

Amgen (AMGN)
WELLCARE HEALTH PLANS, INC. (WCG)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki